▲ +58.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $24.80, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 58.57% upside from the last price of $15.64.
The current consensus among 4 contributing investment analysts is to buy stock in Ocular Therapeutix. This Buy consensus rating has held steady for over two years.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.